Arvinas, Inc. key statistics and ratios
In fiscal 2025, Arvinas, Inc. had return on equity of -16.2%, an operating margin of -45.1%, debt equal to 0.1% of equity and a current ratio of 4.92. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | −326.7% | −305.8% | −119.8% | −466.4% | −351.5% | −200.3% | −511.5% | −95.0% | −45.1% | −5.7% |
| Net margin | −317.3% | −289.6% | −163.5% | −460.6% | −356.3% | −215.0% | −467.9% | −75.5% | −30.8% | 2.9% |
| Free-cash-flow margin | 54.1% | −132.3% | −109.1% | −371.0% | >999% | −213.3% | −446.8% | −99.1% | −105.0% | −65.9% |
| Return on equity | — | −110.1% | −38.7% | −27.5% | −26.8% | −42.0% | −60.0% | −32.6% | −16.2% | 1.9% |
| Return on assets | −36.0% | −31.2% | −28.1% | −23.4% | −16.6% | −19.8% | −28.5% | −16.6% | −8.9% | 1.3% |
| Asset turnover | 0.11 | 0.11 | 0.17 | 0.05 | 0.05 | 0.09 | 0.06 | 0.22 | 0.29 | 0.45 |
| Current ratio | 3.67 | 8.52 | 8.86 | 14.29 | 5.93 | 4.20 | 4.98 | 4.64 | 4.92 | 7.91 |
| Debt to equity | — | 1.6% | 0.9% | 0.3% | 0.1% | 0.2% | 0.2% | 0.1% | 0.1% | 0.1% |
| Interest cover (operating income ÷ interest) | n/m | n/m | n/m | n/m | — | — | — | — | — | — |
| Effective tax rate | — | — | — | — | — | — | — | — | — | 7.9% |
| R&D as % of revenue | 379.9% | 315.5% | 156.3% | 418.5% | 336.6% | 239.7% | 483.7% | 132.2% | 108.6% | 75.4% |
| Capital spending as % of revenue | 13.4% | 19.8% | 14.7% | 24.7% | 8.8% | 5.2% | 3.7% | 0.7% | 0.7% | 0.6% |
| Free cash flow ÷ net income | — | — | — | — | — | — | — | — | — | <−999% |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating margin | −58.9% | −98.3% | 37.8% | −319.2% | −104.5% | −785.3% | −409.0% | 65.7% |
| Net margin | −48.0% | −76.2% | 43.9% | −273.2% | −83.8% | −709.5% | −369.2% | 67.8% |
| Free-cash-flow margin | −125.7% | −142.6% | −47.3% | −431.3% | −141.3% | −322.1% | −451.9% | −19.4% |
| Current ratio | 4.17 | 4.64 | 4.58 | 5.64 | 5.70 | 4.92 | 5.44 | 7.91 |
| Debt to equity | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% |
| R&D as % of revenue | 84.9% | 140.7% | 48.1% | 306.3% | 154.4% | 643.2% | 386.5% | 21.1% |
Financial health
- Short-term assets cover short-term liabilities $652m of assets due within a year against $82m of liabilities due within a year.
- Short-term assets cover long-term liabilities $652m short-term assets against $30m of longer-dated liabilities.
- More cash than debt $94m of cash against $500,000 of debt.
- Debt below 40% of shareholders' equity Debt is 0% of equity.
- Debt burden no higher than five years ago Debt to equity moved from 0% to 0% over five years.
- A year's operating cash flow covers at least 20% of debt −$207m of operating cash flow against $500,000 of debt.
- Operating profit covers interest at least five times over No material interest expense reported.
Moat
Weak moat
How hard Arvinas's competitive advantage looks for rivals to wear away, judged from 9 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 0 / 20
Net income has been a median -25.3% of total assets over 8 years.
- Durability 10 / 20
Operating margin has been a median -208.7%; its worst year was -660.3%.
- Cash conversion 1 / 20
Free cash flow was positive in 1 of 8 years, at a median -164.8% of revenue.
- Discipline 0 / 20
The diluted share count rose 50.2% over five years; stock-based pay has been a median 58.5% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (14 before it).
Compare with peers
- Iovance Biotherapeutics, Inc. statistics
- Adaptive Biotechnologies Corp statistics
- Vericel Corp statistics
- Vir Biotechnology, Inc. statistics
- Syndax Pharmaceuticals Inc statistics
Head to head: ARVN vs IOVAADPT vs ARVNARVN vs VCELARVN vs VIR
More: Biotechnology stocks compared, Health Care sector, rankings of US companies